Biohaven licenses IgG degrader portfolio to Ono for $100M

October 8, 2026 4:00 AM

Biohaven Ltd. (NYSE: BHVN) has entered into a licensing agreement with Ono Pharmaceutical Co., Ltd. (TYO: 4528), granting Ono an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found